Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
AbbVie
Gerd R Burmester; Joel M Kremer; Filip Van den Bosch; Alan Kivitz; Louis Bessette; Yihan Li; Yijie Zhou; Ahmed A Othman; Aileen L Pangan; Heidi S Camp